Having discovered an interesting protein involved in depression and pain, Dr Patrick McHugh, University of Huddersfield, wanted to access chemical tools to further explore its role and action.
He contacted Taros Chemicals for their chemistry expertise and Pivot Park Screening Centre to explore the possibilities of developing an assay. In a collaborative effort, they successfully created a drug discovery programme fulfilling the European Lead Factory standard. The outcome of the screen is promising. Exciting hits were found that will be further explored by the programme partners.
Read the press release here.
Contact the programme office to know more about how you can interact with the European Lead Factory
© European Lead Factory and its partners.
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n' 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7 / 2007-2013) and EFPIA companies' in kind contribution.
This project has also received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806948: ‘ESCulab: European Screening Centre; Unique Library for Attractive Biology’. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Medicines for Malaria Venture (MMV).